Results 71 to 80 of about 54,075 (219)

Image Analysis Platform for Comprehensive Quantification of Extracellular Vesicle Morphology

PROTEOMICS, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐encapsulated nanoparticles with key roles in cell biology and growing importance in biomedicine. However, EVs are challenging to characterize because they are highly heterogeneous. Single EV analysis methods are valuable tools for addressing this challenge.
Alexander Spark, Nan Jiang, Benjamin Purnell, Mihajlo Radmilovic, Andras Saftics, Eugenia Romano, Tijana Jovanovic‐Talisman, Alexandre Kitching   +7 more
wiley   +1 more source

Parallel Analysis of Acidic and Basic Proteoforms in Cell Lysates via Native Cation and Anion Exchange Chromatography—Native Mass Spectrometry

PROTEOMICS, EarlyView.
ABSTRACT Comprehensive characterization of proteoforms in complex biological systems remains a significant challenge. While native ion‐exchange chromatography (IEC) hyphenated with native mass spectrometry (nMS) is a powerful tool for resolving proteoforms, three critical limitations persist: restricted volatile buffers causing nonlinear pH gradients ...
Ziran Zhai, Hafsa Zakri, Matteo Damian, Francesco G. Mutti, Garry Corthals, Andrea F. G. Gargano   +5 more
wiley   +1 more source

MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6

Cellular Physiology and Biochemistry, 2017
Background/Aims: Trastuzumab is an important treatment used for patients with Her-2-positive breast cancer, but an increasing incidence of trastuzumab resistance has been observed clinically during the past decade.
Xiangdong Lu, Jingjing Ma, Jiahui Chu, Qing Shao, Yao Zhang, Guangping Lu, Jun Li, Xiang Huang, Wei Li, Yongfei Li, Yang Ling, Tao Zhao   +11 more
doaj   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Boron‐10 carriers and their applications in boron neutron capture therapy

Precision Radiation Oncology, EarlyView.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
wiley   +1 more source

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

Breast Cancer Research, 2019
Background Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology.
Sònia Palomeras, Ángel Diaz-Lagares, Gemma Viñas, Fernando Setien, Humberto J. Ferreira, Glòria Oliveras, Ana B. Crujeiras, Alejandro Hernández, David H. Lum, Alana L. Welm, Manel Esteller, Teresa Puig   +11 more
doaj   +1 more source

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target

The Prostate, EarlyView.
ABSTRACT Introduction The clinical relevance of HER2 expression profile in solid cancers has expanded with the evolving landscape of HER2 targeting agents. This systematic review and meta‐analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression.
Jacky T. F. Luk, Alex H. Lin, Esther K. C. Cheung, Renald Meçani, Taulant Muka, Jana Nano, Joanna K. M. Ng, Matthew K. L. Chiu, Bryan C. W. Li, Rong Na, Joshua J. X. Li   +10 more
wiley   +1 more source

Endoscope‐Assisted Nipple‐Sparing Mastectomy With Immediate Implant Reconstruction: A Retrospective Study

World Journal of Surgery, EarlyView.
Breast cancer surgery increasingly favors nipple‐sparing and endoscopic techniques to optimize oncological safety, cosmetic outcomes, and patient satisfaction. We aimed to evaluate and compare the clinical efficacy and postoperative safety profiles of endoscope‐assisted and conventional open approaches for nipple‐sparing mastectomy with immediate ...
Yuan Shao, Youcheng Zhang, Huafeng Kang, Qing Zhou, Ziliang Zhang, Guiru Yan, Binghua Kan   +6 more
wiley   +1 more source

Breast Cancer Multi‐Disciplinary Team Meetings in a Resource‐Constrained System: Are Patients Receiving the Treatment Recommended?

World Journal of Surgery, EarlyView.
A total of 556 patients were included in the analyses. Most patients (88%) received primary treatment aligned with the MDT's recommendations. The highest level of concordance was seen in those with early breast cancer who were recommended to have primary surgery (94%), and the lowest in those with metastatic disease.
Nerushka Naidoo, Lindi Martin, Wilhelmina Conradie, Magda Heunis, Charl Petrus Smit, Jenny Edge   +5 more
wiley   +1 more source

Outcomes for Patients With Micro‐Invasive or Small HER2+ Breast Cancer in Northern Sydney Local Health District

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This retrospective study of patients with small, node‐negative HER2+ breast cancer found favorable 5‐year invasive disease‐free survival rates—93% for pT1mic/a disease and 100% for pT1b disease. Trastuzumab was administered to 66% of patients and was associated with larger tumor size and higher histologic grade.
Yuanyuan Xue, Katrina Moore, Tricia Saurine, David Chan, Lina Pugliano, Connie Diakos   +5 more
wiley   +1 more source